Protein-bound paclitaxel

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Retrieved on: 
Monday, April 22, 2024
MSN, Safety, Protein-bound paclitaxel, OTCQB, Prognosis, Survival, Oxaliplatin, Doctor of Philosophy, Therapy, Patient, Fluorouracil, Dicarboxylic acid, Data analysis, PBLA, Pharmaceutical industry

MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.

Key Points: 
  • MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
  • As of the latest assessment, less than half of the required events for the interim analysis have occurred.
  • "The early indications from the ASPIRE trial support this belief, and we remain committed to advancing this important study and look forward to sharing the interim results in March 2025."
  • Panbela will continue to monitor the progress of the ASPIRE trial and provide updates as appropriate.

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

Retrieved on: 
Thursday, April 27, 2023
Oncology, Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, PTC Therapeutics, University, Temozolomide, SPARC, Intron, Schering-Plough, LAPC, Leukemia, PTC, New Drug Application, NDA, TAP, LLS, Associate, Protein-bound paclitaxel, Warburg Pincus, National Cancer Institute, Infliximab, Interferon alfa-2b, Geron Corporation, Patient, PH, Cancer, Merck, FDA, SR, Therapy, Safety, Weill Cornell Medicine, Pharmaceutical industry, MD, Medicine

Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx’s Board.

Key Points: 
  • Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx’s Board.
  • While at Schering-Plough, he served as Sr. Vice President of Worldwide Clinical Research and Chief Medical Officer.
  • Dr. Spiegel completed his Medical Oncology fellowship at the National Cancer Institute and received his MD from the University of Pennsylvania.
  • Our team is also engaging with worldwide regulatory agencies and identifying new indications and combination products utilizing our therapy platform, RenovoTAMP®.”

SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

Retrieved on: 
Thursday, January 26, 2023
IND, Nanoparticle, Blood, SN, Cell, Technology transfer, Behavior, BMS, API, Particle size, Fine chemical, Pharmaceutical industry, Teva, Protein-bound paclitaxel

SN BioScience will receive milestones and double-digit royalties according to the development stage.

Key Points: 
  • SN BioScience will receive milestones and double-digit royalties according to the development stage.
  • SN BioScience also signed a domestic distribution agreement with Boryeong in February 2021 for SNB-101, a polymer nanoparticle new drug, and expects a variety of cooperations in the field of anticancer drugs in the future.
  • "SNA-001" is a product that electrostatically binds cytotoxic anticancer drugs to albumin using albumin present in human blood as a drug carrier.
  • Abraxane is a global blockbuster first developed by Abraxis BioScience Inc (acquired by Celgene who became a subsidiary of BMS), with sales of $1.5 billion worldwide in 2020.

Aadi Bioscience Announces Planned Leadership Transition

Retrieved on: 
Tuesday, November 8, 2022
Constellation, Triple-negative breast cancer, MBA, NASDAQ, COO, KRAS, NYU, TSC2, Pomalidomide, Growth, FDA, Company, TSC1, Private Securities Litigation Reform Act, CCO, NSCLC, Gilead Sciences, Sacituzumab govitecan, Immunomedics, CEO, MorphoSys, Protein-bound paclitaxel, New York University Stern School of Business, Business, AADI, Celgene, Forward-looking statement, Hematology, Lenalidomide, Leadership, Rutgers University, Biology, Marketing, Perivascular epithelioid cell tumour, BS, Risk, Cancer, Time, Management, Pharmaceutical industry, Security (finance), Aadi, Genentech

"I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021.

Key Points: 
  • "I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021.
  • Since that time his expertise and leadership have been instrumental in building the organization in preparation for the growth that lies ahead," saidNeil Desai, Ph.D., Founder, President and Chief Executive Officer ofAadi Bioscience.
  • Going forward, Brendan will assume leadership of the Company as we continue to gain momentum on all of these fronts.
  • Dr. Desai is the founder of Aadi Bioscience and has served as its President and CEO since 2011.

NanoHarmonics Advances Drug Delivery Platform Through Merger with Avagen Pharma

Retrieved on: 
Friday, March 25, 2022
Sale, Data management, Quantum dot, Ownership, Research, Biotechnology, CEO, API, Active ingredient, Pharmacotherapy, Nanotechnology, Technology, Premature ejaculation, Infection, Information technology, Abraxis BioScience, Tuberculosis, SAN, Teva Active Pharmaceutical Ingredients, Quantum, Toxicity, Fine chemical, Pharmaceutical industry, Protein-bound paclitaxel

SAN ANTONIO, Texas, March 25, 2022 /PRNewswire-PRWeb/ -- NanoHarmonics Inc. in line with its strategic plan of integrating innovative drug delivery systems merged with Avagen Pharma Inc. NanoHarmonics, a Quantum Dots bio-diagnostic device company, furthered its interest in the next generation of drug therapy by securing 100% ownership in Avagen Pharma. Avagen is a global distributor of a product designed to help premature ejaculation using an advanced drug delivery system, similar to the technology behind Abraxane, a drug that precipitated the sale of its parent company, Abraxis Bioscience to Celgene for $2.9 billion in 2010.

Key Points: 
  • NanoHarmonics, Inc. has acquired Avagen Pharma, Inc. to further its commitment to converge innovative drug delivery technologies with its current bio-diagnostic and data management platforms to improve the quality of healthcare.
  • Avagen Pharma is a global distributor of products that utilize a patented drug delivery system.
  • SAN ANTONIO, Texas, March 25, 2022 /PRNewswire-PRWeb/ -- NanoHarmonics Inc. in line with its strategic plan of integrating innovative drug delivery systems merged with Avagen Pharma Inc. NanoHarmonics, a Quantum Dots bio-diagnostic device company, furthered its interest in the next generation of drug therapy by securing 100% ownership in Avagen Pharma.
  • Avagen is a global distributor of a product designed to help premature ejaculation using an advanced drug delivery system, similar to the technology behind Abraxane, a drug that precipitated the sale of its parent company, Abraxis Bioscience to Celgene for $2.9 billion in 2010.

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Retrieved on: 
Wednesday, January 26, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, COVID-19, Survival, Risk, Lung, Methoxsalen, MSC, Clinical trial, Uncertainty, U.S. Securities and Exchange Commission, Arm, Patient, Prostate, Annual report, Population, FOLFIRINOX, Phenytoin, Hematological Cancer Research Investment and Education Act, Twitter, Private Securities Litigation Reform Act, Research, Cancer, List of commonly used taxonomic affixes, Pancreatic cancer, Breast, Breast cancer, LinkedIn, MPS, Company, Cell death, Oxidative stress, Protein-bound paclitaxel, Compliance, MD, Learning, Sarcoma, Disease, Nasdaq, Pancreatic Cancer Action Network, Forward-looking statement, Gemcitabine, Pharmaceutical industry, Mobile phone, Medical imaging, Facebook, TYME, TYME Technologies, Inc., SM-88, TYME TECHNOLOGIES, INC., SM-88

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.
  • The Precision Promise trial is an adaptive randomized Phase 2/3 trial in mPDAC for patients treated in both first-line and second-line therapies.
  • Given pancreatic cancers high mortality rate, we wanted to make a difference in the lives of these patients.
  • A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer.

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

Retrieved on: 
Tuesday, November 30, 2021
Patient, Pancreatic cancer, Los Angeles, Cancer, McDiarmid, Technology, EDV, Temperature, Weeping Angel, IIA, Protein-bound paclitaxel, Clinical trial, Therapy, COVID-19, Phase II, Sirna, GLOBE, Globe, Antibody, III, FDA, Asbjørn Engen, Infection, Lists of countries and territories, Immune system, Immunotherapy, NEW, Toxicity, COVID, Brahmbhatt, Pharmaceutical industry, Vaccine

SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment.

Key Points: 
  • SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment.
  • Phase I and IIa trials in patients with advanced pancreatic cancer is underway, and the FDA recently approved another trial in the US.
  • ImmunityBios Executive Chairman is billionaire businessman, doctor and scientist, Patrick Soon-Shiong, who invented the drug Abraxane, used in the treatment of pancreatic cancer.
  • Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV in combination with its anti-cancer drugs and COVID-19 vaccine.

NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Protein-bound paclitaxel, Human, F2, Biology, NGM, Part, Board, Cancer, Drug discovery, Pembrolizumab, Safety, Roger M. Perlmutter, Retina, Lists of diseases, Amgen, Private Securities Litigation Reform Act, AST, Ophthalmology, ESMO, Nash, Oncology, European Society for Medical Oncology, Therapy, Multiple comparisons problem, Cirrhosis, Fibrosis, Leadership, F3, SEC, Injection, Failure, Board of directors, GLOBE, Research, CVM, U.S. Securities and Exchange Commission, Trial of the century, IVT, Patient, COVID-19, Alt, FAF, Geographic atrophy, Risk, Nasdaq, Liver, Pharmaceutical industry, Medical imaging, Cryptocurrency, Fine chemical

NGM anticipates reporting topline data from the CATALINA study in the second half of 2022.

Key Points: 
  • NGM anticipates reporting topline data from the CATALINA study in the second half of 2022.
  • NGM reported a net loss of $36.7million for the quarter ended June30, 2021, compared to a net loss of $25.6 million for the same period in 2020.
  • R&D expenses were $43.6million for the quarter ended June30, 2021, compared to $38.5million for the same period in 2020.
  • General and administrative expenses were $9.8million for the quarter ended June30, 2021, compared to $6.8million for the same period in 2020.

Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Orphan drugs, Drugs, Breast cancer, Health care, Health, Atezolizumab, Breakthrough therapy, Protein-bound paclitaxel, Sarah Cannon Research Institute

The webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC clinical studies, both of which add eganelisib to approved standard of care regimens.

Key Points: 
  • The webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC clinical studies, both of which add eganelisib to approved standard of care regimens.
  • MARIO-3 is a Phase 2 triplet combination study evaluating the addition of eganelisib to the approved standard of care combination of Tecentriq and Abraxane in the front-line setting in TNBC.
  • The webinar will feature a presentation by Erika P. Hamilton, M.D.
  • of Sarah Cannon Research Institute at Tennessee Oncolgy, of updated data from MARIO-3 in the context of the current standard of care.

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Retrieved on: 
Tuesday, July 6, 2021
Carbonyl compounds, Drugs, Cancer treatments, Taxanes, Orphan drugs, Bristol-Myers Squibb, Paclitaxel, Protein-bound paclitaxel, Paclitaxel trevatide

The FDA was supportive and encouraged the Company to continue development of oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

Key Points: 
  • The FDA was supportive and encouraged the Company to continue development of oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
  • We continue to believe that, if approved, oral paclitaxel and encequidar has the potential to address a major unmet need in metastatic breast cancer.
  • Athenex is also developing oral paclitaxel and encequidar for the treatment of cutaneous angiosarcoma, for which it has received Orphan Drug Designation from the FDA.
  • Athenex also received Orphan Designations from the European Commission for oral paclitaxel and encequidar for the treatment of soft tissue sarcoma.